It is a randomized, double-blind, placebo-controlled, multiple-administration, multiple-dose,
dose-escalating, phase Ib/IIa clinical study to evaluate the safety, tolerability, PK and PD
of D-0120 in healthy subjects and hyperuricemia patients (gout or asymptomatic) in China.